The overall goal of this study is to characterize HNSCC for EGFR and HER2 expression and evaluate if trastuzumab and cetuximab can synergize and enhance radiosensitivity in HER2+/EGFR+ HNSCC. Here, ERBB2 is linked to head and neck squamous cell carcinoma.